undamentalytics Newsletter
Sign in

Clene Inc. key statistics and ratios

In fiscal 2025, Clene Inc. had a net margin of -13086.5%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Net margin<−999%<−999%<−999%<−999%<−999%<−999%<−999%
Return on equity—−150.6%—————
Return on assets−28.2%−14.8%−55.6%−102.2%−98.9%−115.1%−192.0%
R&D as % of revenue>999%>999%>999%>999%>999%>999%>999%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

1 of 5 checks passed · June 30, 2026
What it owns · $23m
Short-term assets $15mLonger-term assets $8m
What it owes, and who funded it · $48m
Short-term liabilities $5mLonger-term liabilities $43mShareholders' equity $-25m
  • Short-term assets cover short-term liabilities $15m of assets due within a year against $5m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $15m short-term assets against $43m of longer-dated liabilities.
  • More cash than debt $10m of cash against $18m of debt.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt −$16m of operating cash flow against $18m of debt.
  • Operating profit covers interest at least five times over Operating income of −$21m against $3m of interest.

From Clene Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

12 /100

Weak moat

How hard Clene's competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -73.8% of total assets over 6 years.

  • Durability 10 / 20

    Operating margin has been a median -8700.3%; its worst year was -13753.7%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 6 years, at a median -6192.7% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (17 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: CLDX vs CLNNCLNN vs CRVOCLNN vs IBIO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Clene Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Clene Inc.